UK Community Advisory Board (UK-CAB)

CAB 80: Long-acting agents, CROI and BHIVA feedback

Saturday 23 April 2020

Venue: Gorge House Trust, 75-77 Ardwick Green N, Manchester M12 6FX


09.30-10.00 Arrival, tea and refreshments, expenses
09:50- 10.00 Welcome and introductions
UK-CAB updates
10:00-11:00 Long-acting agents (injectables)- setting the scene for longer-acting drugs and how they work? – Joshua Wharton – George House Trust; Alex SparrowhawkUK-CAB Chair
11.00-11.15 BREAK
11.15-12.15 CROI feedback – Simon Collins
12.15-12.45 Migrants and HIV;  Ukraine and current policy – George Westwood, NAT
12.45-13.45 Lunch (will be delivered at venue)
Chair: Alex Sparrowhawk
13.45-14.45 BHIVA Conference feedback by members

Roger Pebody
Ana Olivieria
Rebecca Walker
Jo Josh

14.45-15:30 UK-CAB online training programme – Ben Cromarty
15:30 -16.00 Members Updates
Meeting reflection
Any other business
16.00 Meeting close

Background reading

HIV i-Base reports from CROI 2022:

• Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
 Injectable CAB/RPV-LA: phase 3b ATLAS-2M results at three years
• Lenacapavir: 6-monthly dosing in treatment-experienced participants and as PrEP in macaques
• Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
• Islatravir studies for HIV treatment and PrEP

• Fourth potential stem cell HIV cure – in a US woman using donor cord cells
• Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs
• Targeting reservoir with ART + bNAb 3BNC117 + romidepsin maintained undetectable viral load off-ART for 3.7 years in one case
• Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
• No impact of high-dose vitamin D3 on reducing the HIV viral reservoir

• Risk factors for NAFLD and proteinuria in HIV positive people on ART
• ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV
• Telomere shortening associated with TAF but not TDF in CHARTER study

• CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
• Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study